‪‎ChoiceBroking‬ ‪‎Financial‬ Tips Morning Tea ‪Buy‬ ‪‎LUPIN‬ @1850-1860 ‪‎TGT1900‬ ‪SL‬ 1840 ‪‎SELL‬ ‪HEROMOTOCO‬ @2643-2655 ‪TGT‬ 2590 SL 2672

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
PharmaMajorLupinhasreceivedfinalapprovalsforitsBlisoviFe1/20Tablets(NorethindroneAcetateandEthinylEstradiolTabletsUSP,1mg/0.02
mgandFerrousFumarateTablets,75mg)andBlisovi1.5/30Tablets(NorethindroneAcetateandEthinylEstradiolTabletsUSP,1.5mg/0.03mgand
Ferrous Fumarate Tablets, 75 mg) from the United States Food and Drug Administration (FDA) to market generic versions of Warner Chilcott's
Loestrin Fe 1/20 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and
Loestrin Fe 1.5/30 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg). The
company's US subsidiary, Lupin Pharmaceuticals Inc. shall commence promoting the product in the US shortly.The company's Blisovi Fe 1/20
Tablets and Blisovi 1.5/30 Tablets are the AB rated generic equivalent of Warner Chilcott's Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets
andareindicatedforthepreventionofpregnancyinwomenwhoelecttouseoralcontraceptivesasamethodofcontraception.
Technical Outlook : The stock has been trading with the support of its rising trend line at 1766 levels on daily chart. Moreover, stock has been
tradingabove200DEMA,whichindicatesthatlongtermtrendisup.AmomentumindicatorRSIreadingisabove40markswithpositivecrossover,
whichpointoutforpositivebreathinthestock.Sofortradingperspective,onecould Buyintherangeof1850-1860fortheTargetof1900withthe
SLof1840.
LUPIN
HEROMOTOCO
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
26th Nov 2015
Sell in the range of 2643-2655 for the Target of 2590 with the SL of 2672
Buy in the range of 1850-1860 for the Target of 1900 with the SL of 1840
US private equity firm Bain Capital is selling shares in Hero MotoCorp , the world's largest seller of motorcycles and scooters, to raise as much as
USD 116 million, IFR reported, citing a person close to the deal. Bain launched the deal to sell 2.98 million Hero shares late on Tuesday in the
indicative price band of between Rs 2,570 and Rs 2,600 each, IFR, a Thomson Reuters publication, said. A spokesman for Hero, which sells about
one in every two motorbikes in India - mainly in the countryside, could not immediately be reached by Reuters for comment. An external
spokesmanforBainCapitalin India didnotimmediately reply toa request seeking comment. Hero shares ended 0.3 percent higher on Tuesdayat
Rs2,645.35. MorganStanleyisthesolebookrunnerforthedeal,IFRsaid.
Technical Outlook : On hourly chart, the stock has been facing resistance of falling trend line at 2698 levels. Moreover, stock has been facing
resistance at 78.60% Fibonacci retracement levels which is previous bearish move of 2794 to 2225 levels. A momentum indicator RSI reading is
with negative crossover on daily chart, which point out for negative breath in the stock. So for trading perspective, one could Sell in the range of
2643-2655 fortheTargetof2590withtheSLof2672.
AsianmarketsroseonThursdayastraderscheeredtheprospectoffreshmonetarystimulusinEurope.Theeurohitafreshseven-and-a-halfmonth
low of USD 1.0632 against the dollar in Asian trade after European Central Bank (ECB) officials told Reuters on Wednesday that they were
considering unconventional easing measures, such as introducing a two tiered deposit rate, ahead of the bank's policy review next week. Those
stimulus expectations saw the STOXX Europe 600 rally 1.3 percent and the German DAX close up more than 2 percent overnight. Shanghai
Compositeindextradedat0.11to3651.87,HangSengindextradedat0.96%to22716.66,Japan'sbenchmarkNikkei225indextradedat0.56%to
19959.26, South Korea's Kospiindex tradedupby0.96 % to2028.90 levels. The SGX Nifty suggests aflattopositive opening forourmarkets asitis
tradingat7843,upby19points.
The major US indexes were virtually unchanged at the close of a quiet trading day on Wednesday with gains in healthcare and consumer stocks
afterdatashowedUSmodesteconomicgrowth.TradingvolumewaslowasmanymarketparticipantswereawayinthelastsessionbeforetheUS
Thanksgiving holiday. Markets is closed today and most of Friday afternoon. The Dow Jones industrial average rose 1.2 points, or 0.01 percent, to
17,813.39, theS&P500lost0.27points,or0.01percent,to2,088.87 andtheNasdaqCompositeadded13.34points,or0.26percent,to5,116.14.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
Natco Pharma Limited; Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share,
Avanti Feeds Limited; Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share.
Result Calendar:
ARVINDREM
26th Nov 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr.No Deal Date Security Name Client Name Deal Type Quantity Price
1 24/11/2015 KYRALANDS INVENTURE GROWTH & SECURITIES LTD. B 1460000 0.51
2 24/11/2015 ADIFINCHM PRIYAM BIMALBHAI PARIKH B 1126535 222.10
3 24/11/2015 KYRALANDS PADHIYAR AND MAHIDHAR TRADING LLP S 1046945 0.50
4 24/11/2015 CMAHENDRA V J COMTRADE PRIVATE LIMITED S 1010979 1.23
5 24/11/2015 PDUMJEIND PRAGYA REALTY DEVELOPERS PRIVATE LIMITED S 999995 12.10
6 24/11/2015 PDUMJEIND J M TRADING CORPORATION B 999995 12.10
7 24/11/2015 JYOTI SIGNORA FINANCE PRIVATE LIMITED B 886270 61.31
8 24/11/2015 JYOTI ORANGE MAURITIUS INVESTMENTS LIMITED S 850000 61.00

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Kapil Shah Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
26th Nov 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Kunal Parmar
Digitally signed by Kunal Parmar
DN: cn=Kunal Parmar, o=Choice Equity Broking
Pvt Ltd., ou=Research Dept.,
email=kunal.parmar@choiceindia.com, c=IN
Date: 2015.11.26 08:39:09 +05'30'